Posts Tagged ‘pharma’

Whether or not we agree with President Trump’s executive orders and policies, on a daily basis, we are getting incredible insight into how he wants to change a number of industries. On Monday, President Trump spoke on reducing regulation and “doing a number” on specific financial rules. Yesterday, he met with executives from the life […]

While we rolled into 2017, I thought it would be neat to see what our readers were, well, reading. Without further ado, here are the top 10 blog posts Perficient’s life sciences practice wrote that seemed to be popular among readers. They’re ranked in order of popularity, with number one being the most viewed piece. The 8 […]

Now that January is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in December – they’re ranked in order of popularity, with number one being the most viewed piece. How Teva Is Leveraging IBM […]

Digital technology has applications throughout clinical studies, from recruitment through data collection. But, it is also being used in exciting and meaningful ways once a drug or device has gone to market, both to improve patient outcomes and to keep sponsors informed. Below are a couple of examples. Huggable, a teddy bear developed by Dr. […]

The area of clinical data collection has seen an influx of rich, digital solutions in recent years, and more continue to enter the marketplace. The plethora of devices, apps, and solutions is aiding in data collection – some within the context of clinical trials and healthcare, others for patients themselves as users and owners of […]

One key area in clinical trials that could benefit from connected health digital solutions is capturing informed consent. Traditionally, patients have signed informed consent forms that are very text-heavy, yet they don’t really understand the rights, responsibilities, risks, and benefits of the study. Explaining the complex details of a trial can add a significant amount […]

In the area of subject recruitment, there are several new technologies that focus on making it easier for companies to recruit, such as reaching a wider population directly for recruitment. Initially, recruitment was handled mostly by physicians and their patients; however reaching patients directly is proving to be very fruitful. One example of a company […]

It seems every company in every industry is talking about “going digital,” but to understand the landscape of life sciences, we must first understand some of the shifts within healthcare that are driving change. Below are some trends that are reshaping healthcare and, therefore, life sciences, and are making it harder and harder for life […]

According to the 2016 Summit Site Landscape Survey, which was conducted by the Society for Clinical Research Sites, the majority of clinical sites aren’t feeling the love from sponsors and CROs. Of the 463 survey respondents, only 31% felt their relationship with sponsors had improved in the past two years, and only 25% felt that […]

Now that December is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in November – they’re ranked in order of popularity, with number one being the most viewed piece. 10 Headlines That Suggest Donald Trump […]

As one of Salesforce’s strategic partners, I’m glad to share the success Eli Lilly is having with the Salesforce platform. According to a press release that was issued by Salesforce, the pharmaceutical company has launched 50+ internal and external applications over the last two years. TrialGuide is one example. The website, which is naturally mobile-friendly, […]

This year’s presidential election invoked serious fear in the pharmaceutical industry, with the cost of drugs taking center stage for a good portion of some candidates’ campaigns. While what candidates say they’ll do could very well be different than what they’ll try to do, their words and records are enough to push pundits, investors, and […]